全球铜绿假单胞菌感染药物市场2022-2029

市场动态

由铜绿假单胞菌引起的医院感染增加

铜绿假单胞菌药物市场增长的主要因素是铜绿假单胞菌引起的医院感染增加、抗菌素耐药性的快速增加以及治疗铜绿假单胞菌的药物研发的增加感染。

与铜绿假单胞菌相关的医院感染率上升，如尿路感染 (UTI)、肺炎、囊性纤维化和血流感染，将在预测期内推动全球铜绿假单胞菌药物市场的增长，预计将推动预计重症监护病房中铜绿假单胞菌感染率的上升将推动对新铜绿假单胞菌治疗的需求。根据美国疾病控制和预防中心 (CDC) 的数据，美国每年发生大约 51,000 例与医疗保健相关的铜绿假单胞菌感染。其中，超过 6,000 种（13%）是多重耐药菌，每年约有 400 人死于这些感染。已发现医院获得性感染 (HAI) 死亡率增加是由于铜绿假单胞菌所致，尤其是在免疫功能低下的患者中。大约 35% 的医疗相关感染会导致呼吸道、泌尿、胃肠道和其他疾病，导致对铜绿假单胞菌药物的需求增加。

在治疗铜绿假单胞菌感染中增加使用抗生素也促进了市场增长。由于越来越多地使用抗生素治疗铜绿假单胞菌感染，耐抗生素细菌的出现使这种治疗基本上无效。在这种情况下，製药公司正专注于开发抗药性细菌的治疗方法。这为铜绿假单胞菌感染治疗市场的参与者提供了充足的空白空间。

不断增加的投资和广泛的研发正在推动新疗法的发展。主要参与者正在大力投资于非抗生素治疗方案的研发。几家製药公司正在测试与抗生素化学相似的新型化合物。预计研发资金的增加将推动市场增长。例如，2021 年 11 月，PlateletBio 是一家临床前阶段的公司，投资于开发同种异体细胞治疗的新方法，在 B 轮融资中筹集了 7550 万美元，以推进该领域的开创性方法。该公司正在开发基于血小板生物学的新型同种异体细胞疗法。该公司的主要候选人正在进行自身免疫性疾病免疫性血小板减少症（ ITP ）的临床前开发。 2022年7月，处于临床阶段的生物技术公司Carmot Therapeutics, Inc.将加入旨在发现和开发代谢疾病和癌症疾病修饰疗法的药物发现平台Chemotype Evolution，宣布投资6000万美元。

但是，长期使用抗生素可能会对患者产生不利影响并阻碍市场增长。然而，由于铜绿假单胞菌表现出耐药性，资金有限的药物研发公司纷纷退出市场。

内容

第一章研究方法与范围

• 调查方法
• 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

• 按治疗划分的市场细分
• 按药物类别划分的市场细分
• 按管理途径划分的市场细分
• 按分销渠道划分的市场细分
• 按地区划分的市场细分

第 4 章市场动态

• 市场影响因素
  • 驱动程序
    • 医院获得性感染 (HAI) 增加
    • 增加对铜绿假单胞菌药物研发的投资
  • 限制因素
    • 铜绿假单胞菌的耐药能力
• 商机
• 影响分析

第五章行业分析

• 波特五力分析
• 流行病学
• 管道分析
• 供应链分析
• 定价分析
• 监管分析
• 未满足的需求
• COVID-19 影响分析

第 6 章治疗

• 单一疗法
• 联合疗法

第 7 章按药物类别

• 氨基糖甘类
• 单巴坦系统
• 碳青霉烯类
• 头孢菌素
• 其他

第 8 章给药途径

• 鼻腔
• 口语
• 静脉给药

第 9 章按分销渠道

• 医院药房
• 零售药房
• 在线药店
• 其他

第 10 章按地区划分

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 其他欧洲
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 其他亚太地区
• 中东和非洲

第 11 章竞争格局

• 竞争场景
• 市场情况/份额分析
• 併购分析

第 12 章公司简介

• Teva Pharmaceutical Industries Ltd.
  • 公司概况
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• AbbVie Inc.（Allergan plc）
• Pfizer, Inc.
• Merck & Co., Inc.
• AstraZeneca
• Bristol-Myers Squibb Co.
• Lupin Pharmaceuticals, Inc.
• Janssen Pharmaceuticals, Inc.
• Gilead Sciences Inc.
• Novartis AG（LIST NOT EXHAUSTIVE）

第13章 DataM

Market Overview

Pseudomonas aeruginosa infection treatment market was valued at USD 1.31 billion in 2021. It is forecasted to reach USD YY million by 2029, growing at a CAGR of 6.5% during the forecast period (2022-2029).

Pseudomonas Aeruginosa (also known as P. aeruginosa) is an important cause of gram-negative infection, especially in patients with compromised host defense mechanisms. Pseudomonas aeruginosa is a multidrug-resistant pathogen known for its intrinsically advanced antibiotic resistance mechanisms, its antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections (HAIs) such as ventilator-associated pneumonia and various sepsis syndromes. These bacteria frequently cause urinary tract infections (UTIs), lung infections, pneumonia, and chronic pain. People with a low immune system are highly prone to affect by this infection.

The incidence of Hospital Acquired Infections (HAIs) has increased in recent years. As P. aeruginosa infection is one of the common infections in a hospital facility, the chances of being diagnosed with P. aeruginosa infection are high. This has led to an increase in research and development to find the treatment for P. aeruginosa. Several drugs are in the pipeline phases for the treatment of this infection.

Market Dynamics: rising incidences of nosocomial infections associated with P. aeruginosa

The pseudomonas aeruginosa infection treatment market growth is majorly driven by the rising incidences of nosocomial infections associated with P. aeruginosa, rapidly growing antibacterial resistance, and increasing research & development of pseudomonas aeruginosa infection treatments.

The rise in the prevalence of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others, are expected to drive the growth of the global pseudomonas aeruginosa infection treatment market over the forecast period. There is a rise in the incidence of pseudomonas aeruginosa infections in intensive care which is projected to boost the demand for newer pseudomonas aeruginosa infection treatment drugs. As per the Centers for Disease Control and Prevention (CDC), about 51,000 healthcare-associated pseudomonas aeruginosa infections occur in the United States annually. Over 6,000 (13%) of these are multidrug-resistant, with around 400 deaths per year attributed to these infections. The growing mortality rate owing to hospital-acquired infection(HAIs) is caused due to P. aeruginosa bacteria, especially in immunocompromised hosts. About 35 % of healthcare-acquired infections cause respiratory system infections, urinary infections, gastrointestinal infections, and other disorders, which leads to a rise in the demand for pseudomonas aeruginosa treatment.

In addition, increasing the usage of antibiotics for the treatment of pseudomonas aeruginosa infection is also driving market growth. Owing to the increasing use of antibiotics for the treatment of P. aeruginosa infection, the emergence of antibiotic-resistant bacterial strains has this line of treatment almost ineffective. In this scenario, pharma companies are focused on developing a treatment approach for the same. This provides ample white space for players in the pseudomonas aeruginosa infection treatment market to capitalize on.

The rising investments and extensive research & development are boosting the development of novel therapies. The major players are investing heavily in R&D for non-antibiotic treatment options. Several pharma companies are testing novel compounds that bear chemical similarities with antibiotics. Increasing funding for research and development is expected to boost market growth. For instance, in November 2021, PlateletBio, a preclinical stage company that invested in developing a new approach to allogeneic cell therapies, raised $75.5 million in a Series B financing round to advance its pioneering approach to the field. The company is developing new allogeneic cell therapies based on platelet biology. Its lead candidate is in preclinical development for immune thrombocytopenia (ITP), an autoimmune disease. Also, in July 2022, Carmot Therapeutics, Inc., a clinical-stage biotechnology company announced to invest 160 million USD financing for drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer.

However, extended use of antibiotics leads to harmful effects on the patient, which is likely to hamper the market growth. However, as P. aeruginosa shows the ability of drug resistance, several drug developers, who have limited funds are dissuaded from the market.

Market Segmentation: therapy segment for the highest share in global pseudomonas aeruginosa infection treatment market

The pseudomonas aeruginosa infection treatment market is classified by medication into monotherapy and combination therapy. Among these, the combination therapy segment accounted for the largest market share in the global pseudomonas aeruginosa infection treatment market in 2021. Combination therapy is used for the patient who has developed resistance property against monotherapy. During this therapy, a combination of different drugs is used to treat bacterial infections. The rise in drug resistance in monotherapy has increased the demand for combination therapy for the treatment of pseudomonas aeruginosa infection. As per the research, combination therapy showed promising results and the mortality was lower in patients receiving combination therapy, compared to monotherapy. Also, the growth of combination therapy for the treatment of P. aeruginosa infection is due to its rapid onset of action, high bioavailability rate, cost-saving, and high efficiency. Hence, these factors are expected to boost the growth of the combination therapy segment.

Based on drug class, the global pseudomonas aeruginosa infection treatment market is segmented into cephalosporin, aminoglycoside, carbapenem, monobactam, and others Among these, the cephalosporin segment held the largest market share in 2019, owing to the increasing development of a new class of cephalosporin for the treatment of various P. aeruginosa infections by significant companies. A new cephalosporin (fifth-generation) was developed for the treatment of gram-negative bacteria such as P. aeruginosa, methicillin-resistant staphylococcus aureus, and others. The launch of a new cephalosporin class of drugs is likely to boost the growth of the segment.

Based on the route of administration, the global pseudomonas aeruginosa infection treatment market has been segmented into oral, nasal, and intravenous. The intravenous segment is expected to dominate the global pseudomonas aeruginosa infection treatment market during the forecast period because most of the drugs available for the intravenous route as it gives rapid onset of action and high accuracy in dosing compared with other routes. Most physicians prefer the intravenous route for the administration of drugs, as in the intravenous route, the entire dose reaches the systemic circulation immediately with rapid onset of action against bacteria.

Geographical Penetration: North America is the dominating region during the forecast period.

North America region is dominating the global pseudomonas aeruginosa infection treatment market accounted for the largest market share in 2021, owing to rising incidences of nosocomial infections associated with P. aeruginosa, such as urinary tract infection (UTIs), pneumonia, cystic fibrosis, bloodstream infection, and others. As per the the Centers for Disease Control (CDC) estimates that HAIs account for an estimated 1.7 million infections and 99,000 associated deaths each year. In addition, 32 percent of all healthcare-acquired infection are urinary tract infections and 22 percent are surgical site infections. According to the Provincial Infection Control Network of British Columbia, HAIs are a major patient safety issue and economic burden for the healthcare system. In Canada, one in every nine hospital patients contracts a healthcare-associated infection. It is estimated that each year in Canada, there are more than 220,000 cases of HAI in Canada hospitals, resulting in at least 8,000 deaths. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries. The U.S. and Canada have a well-developed health care system that encourages research and development for the treatment of these infections. These countries have a major presence of diverse global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Europe is the second-largest market for pseudomonas aeruginosa infection treatment in terms of market value, due to rising incidences of pseudomonas aeruginosa infection, the presence of major players, and the early adoption of new products. For instance, in Germany, about 22,000 to 33,000 people are suffering from pseudomonas aeruginosa infection.

The Asia-Pacific pseudomonas aeruginosa infection treatment market is expected to grow at the fastest growth rate over the forecast period. Developing countries such as China, India, and South Korea are expected to be lucrative markets over the forecast period, owing to growing awareness, increasing incidences of healthcare-associated pseudomonas aeruginosa infection, rapidly developing healthcare infrastructure, and high demand for advanced therapeutics. About 165,000 to 180,000 people in Australia suffer from hospital-acquired infections, as per a study, and of these, about 9,000 have pseudomonas aeruginosa infection.

Competitive Landscape:

The global players are manufacturing the majority of the pseudomonas aeruginosa infection treatment drugs and therapies. Some of the key players which are contributing to the growth of the market include AbbVie Inc. (Allergan plc), Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Co., Lupin Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Gilead Sciences Inc., Novartis AG, among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the pseudomonas aeruginosa infection treatment market globally. For instance

In April 2021, CARB-X funded up to 5.3 million USD to Phico therapeutics to develop an engineered bacteriophage drug to treat ventilator-associated pneumonia caused by drug-resistant pseudomonas aeruginosa.

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., launched generic erythromycin tablets in the USA. Teva generic Erythromycin tablets are indicated to treat a variety of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin. The tables are available in sizes of 250 mg and 500 mg.

In September 2019, Armata Pharmaceuticals, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, has developed a new synthetic phage candidate targeting the pathogen Pseudomonas aeruginosa to treat serious respiratory infections, with an emphasis on cystic fibrosis patients.

In March 2019, Allergan received the U.S. FDA approval for the AVYCAZ treatment of complicated intra-abdominal infections (cIAI) and urinary tract infections (cUTI) in pediatric patients.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Treatment
• 3.2. Market snippet by Drug Class
• 3.3. Market snippet by Route of Administration
• 3.4. Market Snippet by Distribution Channel
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Prevalence of Hospital Acquired Infections (HAIs)
    • 4.1.1.2. Growing Investment in Drug Discovery for Pseudomonas Aeruginosa
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. Drug Resistance Ability of Pseudomonas Aeruginosa
    • 4.1.2.2. XX
• 4.2. Opportunity
• 4.3. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Epidemiology
• 5.3. Pipeline Analysis
• 5.4. Supply Chain Analysis
• 5.5. Pricing Analysis
• 5.6. Regulatory Analysis
• 5.7. Unmet Needs
• 5.8. COVID-19 Impact Analysis

6. By Treatment

• 6.1. Introduction
• 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Segment
• 6.3. Market Attractiveness Index, By Treatment Segment
  • 6.3.1. Monotherapy*
    • 6.3.1.1. Introduction
    • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 6.3.2. Combination Therapy

7. By Drug Class

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
• 7.3. Market Attractiveness Index, By Drug Class Segment
  • 7.3.1. Aminoglycoside*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Monobactam
  • 7.3.3. Carbapenem
  • 7.3.4. Cephalosporin
  • 7.3.5. Others

8. By Route of Administration

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration Segment
• 8.3. Market Attractiveness Index, By Route of Administration Segment
  • 8.3.1. Nasal*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Oral
  • 8.3.3. Intravenous

9. By Distribution Channel

• 9.1. Introduction
• 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
• 9.3. Market Attractiveness Index, By Distribution Channel Segment
  • 9.3.1. Hospital Pharmacies*
    • 9.3.1.1. Introduction
    • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 9.3.2. Retail Pharmacies
  • 9.3.3. Online Pharmacies
  • 9.3.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.7.1. U.S.
    • 10.2.7.2. Canada
    • 10.2.7.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.7.1. Germany
    • 10.3.7.2. U.K.
    • 10.3.7.3. France
    • 10.3.7.4. Italy
    • 10.3.7.5. Spain
    • 10.3.7.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.7.1. Brazil
    • 10.4.7.2. Argentina
    • 10.4.7.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.7.1. China
    • 10.5.7.2. India
    • 10.5.7.3. Japan
    • 10.5.7.4. Australia
    • 10.5.7.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
  • 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Teva Pharmaceutical Industries Ltd.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. AbbVie Inc. (Allergan plc)
• 12.3. Pfizer, Inc.
• 12.4. Merck & Co., Inc.
• 12.5. AstraZeneca
• 12.6. Bristol-Myers Squibb Co.
• 12.7. Lupin Pharmaceuticals, Inc.
• 12.8. Janssen Pharmaceuticals, Inc.
• 12.9. Gilead Sciences Inc.
• 12.10. Novartis AG (LIST NOT EXHAUSTIVE)

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us